For example, evinacumab, an antibody that inhibits ANGPTL3 not only reduces TG level in circulation by enhancing LPL activity but also significantly decreases low-density lipoprotein cholesterol (LDL-C) in patients with familial hypercholesterolemia (FH) in two independent phase 3 trials (5, 6). The gene discussed is LPL; the disease is familial hypercholesterolemia.